- Home
- ORIC vs KROS Comparison
ORIC vs KROS Comparison
Compare ORIC & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- KROS
- Stock Information
- Founded
- ORIC 2014
- KROS 2015
- Country
- ORIC United States
- KROS United States
- Employees
- ORIC N/A
- KROS N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- ORIC Health Care
- KROS Health Care
- Exchange
- ORIC Nasdaq
- KROS Nasdaq
- Market Cap
- ORIC 633.7M
- KROS 589.8M
- IPO Year
- ORIC 2020
- KROS 2020
- Fundamental
- Price
- ORIC $9.90
- KROS $11.44
- Analyst Decision
- ORIC Strong Buy
- KROS Buy
- Analyst Count
- ORIC 9
- KROS 11
- Target Price
- ORIC $18.75
- KROS $45.33
- AVG Volume (30 Days)
- ORIC 585.0K
- KROS 1.9M
- Earning Date
- ORIC 03-10-2025
- KROS 02-26-2025
- Dividend Yield
- ORIC N/A
- KROS N/A
- EPS Growth
- ORIC N/A
- KROS N/A
- EPS
- ORIC N/A
- KROS N/A
- Revenue
- ORIC N/A
- KROS $651,000.00
- Revenue This Year
- ORIC N/A
- KROS $303.27
- Revenue Next Year
- ORIC N/A
- KROS N/A
- P/E Ratio
- ORIC N/A
- KROS N/A
- Revenue Growth
- ORIC N/A
- KROS 8037.50
- 52 Week Low
- ORIC $6.33
- KROS $9.78
- 52 Week High
- ORIC $16.65
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- ORIC 56.99
- KROS 22.23
- Support Level
- ORIC $9.39
- KROS $9.78
- Resistance Level
- ORIC $11.15
- KROS $11.63
- Average True Range (ATR)
- ORIC 0.75
- KROS 0.85
- MACD
- ORIC 0.20
- KROS 1.14
- Stochastic Oscillator
- ORIC 62.92
- KROS 21.16
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.